Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05496725
Other study ID # YSP-RNH3001-01
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 6, 2022
Est. completion date July 28, 2022

Study information

Verified date August 2022
Source Yung Shin Pharm. Ind. Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of micafungin (50 mg/vial) after intravenous infusion of 50 mg micafungin in healthy volunteers under fasting conditions


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date July 28, 2022
Est. primary completion date May 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: 1. Healthy adult male or female subjects between 20-45 years of age (inclusive) at the screening visit. 2. Body mass index (BMI) between 18 and 27 kg/m2 (not inclusive) at the screening visit. 3. Acceptable medical history and physical examination including: - no particular clinically significant abnormalities in ECG results within six months prior to Period I dosing. - no particular clinical significance in general disease history within two months prior to Period I dosing. 4. Acceptable biochemistry determinations (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes AST (SGOT), ALT (SGPT), ?-GT, alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol and triglyceride (TG). 5. Acceptable hematology (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials and platelets. 6. Acceptable urinalysis (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes pH, blood, glucose, ketones, bilirubin and protein. 7. Female of childbearing potential practicing an acceptable method of birth control for the duration of the study. 8. Have signed the written informed consent to participate in the study. Exclusion Criteria: 1. A clinically significant disorder involving the cardiovascular, respiratory, hepatic, renal, urinary tract, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease. 2. A clinically significant illness or surgery within four weeks prior to Period I dosing. 3. History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder disease, pancreas disorder over last two years or history of gastrointestinal tract surgery over last five years. 4. History of kidney disease or urination problem over last two years deemed by the investigator to be clinically significant. 5. Known or suspected history of drug abuse within lifetime. 6. History of alcohol addiction or abuse within last five years or use of more than 7 units of alcohol per week within two weeks prior to dosing. (1 unit of alcohol = 10 g of alcohol or about 350 mL of beer or about 83 mL of red wine or about 30 mL of beverage containing 40% (v/v) alcohol). 7. History of allergic response(s) to palonosetron or any other related drugs. 8. Evidence of chronic or acute infectious diseases. 9. Positive result for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV). 10. Female subjects demonstrating a positive pregnancy screen prior to the study. 11. Female subjects who are currently breastfeeding. 12. Taking any drug known to induce or inhibit hepatic drug metabolism within four weeks prior to Period I dosing. Examples of inducers include: piperidines, carbamazepine, dexamethasone and rifampin. Examples of inhibitors include: cimetidine, diphenhydramine, fluvastatin, methadone and ranitidine. 13. Taking any prescription medications within four weeks or any nonprescription medications (excluding flu vaccination) within two weeks prior to Period I dosing. 14. Use of any investigational drug within four weeks prior to Period I dosing. 15. Use of any COVID-19 vaccine within seven days prior to Period I dosing. 16. Donating more than 250 mL of blood within two months prior to Period I dosing or donating plasma (e.g. plasmapheresis) within two weeks prior to Period I dosing. 17. Any other medical reason as determined by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Micafungin
Pharmacokinetic study under fasting conditions

Locations

Country Name City State
Taiwan Taichung Veterans General Hospital Taichung

Sponsors (1)

Lead Sponsor Collaborator
Yung Shin Pharm. Ind. Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak plasma concentration (Cmax) 0 (pre-dose), 20 and 40 minutes, and 5, 15, 30 minutes, 1, 2, 3, 5, 7, 11, 23, 35,47 and 59 hours post dose
Primary Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t) 0 (pre-dose), 20 and 40 minutes, and 5, 15, 30 minutes, 1, 2, 3, 5, 7, 11, 23, 35,47 and 59 hours post dose
Primary Area under the concentration-time curve from time zero to infinity (AUC 0-8) 0 (pre-dose), 20 and 40 minutes, and 5, 15, 30 minutes, 1, 2, 3, 5, 7, 11, 23, 35,47 and 59 hours post dose
Primary Ratio of area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t) to Area under the concentration-time curve from time zero to infinity (AUC 0-8) Calculate the ratio between Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t) and Area under the concentration-time curve from time zero to infinity (AUC 0-8). It require no less than 0.8. 0 (pre-dose), 20 and 40 minutes, and 5, 15, 30 minutes, 1, 2, 3, 5, 7, 11, 23, 35,47 and 59 hours post dose
See also
  Status Clinical Trial Phase
Recruiting NCT05763251 - Comparison of Uncomplicated Candidemia Therapy Duration in Children N/A
Recruiting NCT01438216 - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients N/A
Terminated NCT01213823 - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Phase 4
Completed NCT02491151 - Variability of Fluconazole Concentration in Critically Ill Patients N/A
Completed NCT01716988 - Pharmacokinetics of Micafungin in Critically Ill Patients N/A
Completed NCT00607763 - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00608335 - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00786903 - Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen? N/A
Completed NCT00670657 - CRITIC - Treatment of Candidemia and Invasive Candidiasis Phase 4
Recruiting NCT04368559 - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 3
Not yet recruiting NCT05707832 - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus Phase 3
Recruiting NCT03538912 - Early Discontinuation of Empirical Antifungal Therapy and Biomarkers N/A
Completed NCT02801682 - NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
Completed NCT02164890 - Pharmacokinetics of Micafungin in Patients of Intensive Care Units Phase 4
Completed NCT02841501 - Genetic Susceptibility Factors for Candidemia.
Completed NCT01047267 - Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU) N/A
Completed NCT00672841 - β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients N/A
Completed NCT02734862 - CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Phase 2
Completed NCT01773876 - Empirical Antifungal Treatment in ICUS Phase 3
Completed NCT00689338 - Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Phase 3